Xylos Corporation to Report on Significant Biocellulose Technology Advances at the In3 East...

LANGHORNE, Pa. -- Xylos Corporation ("Xylos" or the "Company") is presenting a technology and business update on its developments in unique biocellulose-based medical devices and combination drug / device "convergence" technology at the Investment In Innovation (In3) Medical Device Summit in Boston,

The Company's update will include key advances regarding:

* Progress of its human clinical trial in dura repair, representing validation for Xylos' biomaterial as a safe and effective implantable medical device

* Clinical experiences in convergence applications (medical devices that incorporate drugs or other active agents)

* Commercial expansion in international markets

Xylos develops superior solutions for the treatment, repair and replacement of human tissue. The Company is focused on product pipelines covering surgical implants, drug delivery and skin care products. With FDA-cleared products, an existing revenue stream, and highly focused product pipelines, the Company is targeting market opportunities of $4.6 billion (U.S.).

Mark S. McNulty, Chief Executive Officer, stated "We are pleased with the continuing clinical validation of our technology in surgical implants, drug delivery and skin care applications. These achievements are critical milestones in our business plan and represent significant differentiation and competitive advantage in the marketplace."

Xylos' technology is based upon a proprietary biocellulose material and the ability to bioengineer this material into medical devices that are safe, biocompatible, have no known risk of disease transmission, have no limitation on availability and can be engineered to meet precise product performance requirements. The unique structure of Xylos' biocellulose material endows it with a natural fluid holding capacity of approximately 100 times its dry weight, excellent tensile strength, and shape retention superior to many synthetic fibers. Due to minimal molecular binding sites within the material, it has the inherent ability to efficiently deliver drugs, growth factors and other active agents and potentially reduce the quantity of active agent needed for effective therapy.

Additional information on Xylos is available at www.xyloscorp.com or by contacting Mark S. McNulty, Chief Executive Officer at 215-867-0220 x604 (mark.mcnulty@xyloscorp.com). Information on the In3 conference is available at http://www.medtechinsight.com/in3-18.html.